Resitu: minimally invasive surgical technology

Helping us establish the Resitu technology – Investors

With support from our investors, the Resitu technology has the potential to become the globally preferred method to treat breast cancer.

Based on an invention by surgeon Per Hedén

The Resitu technology for minimally invasive surgery is built on a patented invention by surgeon Per Hedén.

Product launch in 2023

Resitu plan to launch the first product in EU and US in 2023. The first line of products will focus on biopsy and breast tissue removal

Major shareholders

In 2021-2022 Resitu Medical raised seed capital to reach the final product design and to start series production and perform clinical trials towards CE mark and FDA clearance for our first product. Our major shareholders are Novoaim (63%), ALMI Invest Stockholm (13%) and STOAF (13%).

Upcoming rounds

Series A and B rounds are planned in 2023 and 2025 to enable clinical studies, expand into additional markets and for further product development to launch the second-generation product.


Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.